Application of a pharmacogenetic test adoption model to six oncology biomarkers

被引：13

作者：

Faruki, Hawazin ^{[1
]}

Lai-Goldman, Myla ^{[1
]}

机构：

[1] Lab Corp Amer, Res Triangle Pk, NC USA

来源：

PERSONALIZED MEDICINE | 2010年 / 7卷 / 04期

关键词：

BCR-ABL; CYP450; EGFR expression; HER2; KRAS; oncology; personalized medicine; pharmacogenomic tests; test adoption; UGT1A1; genotype; COLORECTAL-CANCER PATIENTS; GROWTH-FACTOR RECEPTOR; TAMOXIFEN METABOLISM; AMERICAN-SOCIETY; CYP2D6; GENOTYPE; ADJUVANT BREAST; SURVIVAL; RECOMMENDATIONS; CLOPIDOGREL; INHIBITORS;

D O I：

10.2217/PME.10.37

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The ability of genomics to match precise information about the molecular biology of a cancer with the available present and future therapeutics offers tremendous promise for cancer patients. Unfortunately, few genomic-based tests or treatments are available today to benefit these patients. Using a pharmacogenetic test adoption model, previously introduced to model the adoption of HLA-B*5701 testing for abacavir hypersensitivity, six oncology biomarkers, HER2, BCR-ABL quantitation, KRAS mutation, UGT1A1, CYP2D6 for tamoxifen and EGFR expression, test adoption patterns are explored. Developmental milestones and emerging scientific knowledge relating to each of the biomarkers are discussed in the context of their impact on test ordering patterns. Through analysis of the adoption patterns of multiple cancer biomarkers, a pharmacogenetic model emerges which appears to be applicable in five of the six biomarkers. This model may be useful in predicting adoption patterns of new markers and in providing guidance to drug and test developers introducing personalized medicine applications.

引用

页码：441 / 450

页数：10

共 44 条

[1] American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].

Allegra, Carmen J. ;

Jessup, J. Milburn ;

Somerfield, Mark R. ;

Hamilton, Stanley R. ;

Hammond, Elizabeth H. ;

Hayes, Daniel F. ;

McAllister, Pamela K. ;

Morton, Roscoe F. ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096

[2]

[Anonymous], 2004, CLIN PRACT GUID ONC

[3]

[Anonymous], 2011, Aetna Clinical Policy Bulletin: Home Births

[4]

[Anonymous], CIGNA MED COVERAGE P

[5] Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? [J].

Berg, Alfred O. ;

Armstrong, Katrina ;

Borkin, Jeffrey ;

Calonge, Ned ;

Haddow, James ;

Hayes, Maxine ;

Kaye, Celia ;

Phillips, Kathryn A. ;

Piper, Margaret ;

Richards, Carolyn Sue ;

Scott, Joan A. ;

Strickland, Ora L. ;

Teutsch, Steven .

GENETICS IN MEDICINE, 2009, 11 (01) :15-20

[6]

*BLUECROSS BLUESHI, 2009, TECHN EV CTR KRAS MU

[7]

*BLUECROSS BULESHI, CYP2D6 PHARM TAM TRE

[8] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

De Braud, F. G. ;

Volovat, C. ;

Nippgen, J. ;

Stroh, C. ;

Celik, I. ;

Koralewski, P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[9] Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment [J].

Borges, Silvana ;

Desta, Zeruesenay ;

Li, Lang ;

Skaar, Todd C. ;

Ward, Bryan A. ;

Nguyen, Anne ;

Jin, Yan ;

Storniolo, Anna Maria ;

Nikoloff, D. Michele ;

Wu, Lin ;

Hillman, Grant ;

Hayes, Daniel F. ;

Stearns, Vered ;

Flockhart, David A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :61-74

[10]

Center for Medicare and Medicaid Services Office of Clinical Standards and Quality Coverage and Analysis Group, 2010, SUMM MED EV DEV COV

← 1 2 3 4 5 →